

August 30, 2018



Rexahn Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

ROCKVILLE, Md., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced that Peter D. Suzdak, Ph.D., the Company's chief executive officer, will present a corporate overview at the 20th Annual Rodman & Renshaw Global Investment Conference sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 4-6, 2018 in New York City.

Presentation Details:

Date: Thursday, September 6

Time: 9:35 am Eastern Time

Location: The St. Regis New York, in Library (2nd floor)

Webcast: A live audio webcast of the presentation will be available and can be accessed through the following hyperlink <http://www.wsw.com/webcast/rrshq28/rnn/>, or from the Company's website, under the "Investor Relations - Events and Presentations" section.

About Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals Inc. (NYSE American:RNN) is a clinical stage biopharmaceutical company dedicated to developing novel, targeted therapeutics for the treatment of cancer. The company's mission is to improve the lives of cancer patients by developing next-generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally associated with cancer treatment. Rexahn's product candidates work by targeting and neutralizing specific proteins believed to be involved in the complex biological cascade that leads to cancer cell growth. Preclinical studies show that certain of Rexahn's product candidates may be effective against multiple types of cancer, including drug resistant cancers, and difficult-to-treat cancers, and others may augment the effectiveness of current FDA-approved cancer treatments. The company has two oncology product candidates, RX-3117 and RX-5902, in Phase 2 clinical development and additional compounds in preclinical development including RX-0201. For more information about the Company and its oncology programs, please visit www.rexahn.com.

Media Contact:

DGI Comm

Susan Forman or Laura Radocaj

+1-212-825-3210

sforman@dgicomm.com

lradoaj@dgicomm.com

Investor contact:

ir@rexahn.com



Source: Rexahn Pharmaceuticals